login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
SUMMIT THERAPEUTICS INC (SMMT) Stock News
USA
-
Nasdaq
- NASDAQ:SMMT -
US86627T1088
-
Common Stock
17.29
USD
-0.55 (-3.08%)
Last: 11/25/2025, 2:18:00 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
SMMT Latest News, Press Relases and Analysis
All
Press Releases
8 days ago - By: Zacks Investment Research
- Mentions:
MRK
MRNA
CDTX
MRK Up Nearly 10% in a Month: Should You Buy, Sell or Hold the Stock?
15 days ago - By: Zacks Investment Research
- Mentions:
MRK
MRNA
Will Keytruda Aid MRK's Growth in 2026 After a Subdued Q3?
18 days ago - By: Summit Therapeutics
Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China
21 days ago - By: Summit Therapeutics
Summit Therapeutics to Present at Upcoming Investor Conferences
a month ago - By: Benzinga
- Mentions:
CNS
FCN
Alpha Buying: When Insiders Buy Big & Why It Works in Every Market
25 days ago - By: Summit Therapeutics
Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025
a month ago - By: The Motley Fool
1 Monster Stock in the Making to Buy and Hold
a month ago - By: The Motley Fool
Summit Therapeutics: A Risky Bet in the Biotech Arena?
a month ago - By: Summit Therapeutics
Summit Therapeutics Raises $500 Million in Private Placement
a month ago - By: Stocktwits
Summit Therapeutics Stock Sparks Retail Buzz After Ivonescimab Combo Cuts Cancer Progression Risk By 40%
a month ago - By: Benzinga
An Overview of Summit Therapeutics's Earnings
a month ago - By: Bloomberg
Summit Seeks Cancer Drug’s Approval Despite US Regulator Warning
2 months ago - By: Stocktwits
Summit Therapeutics Stock Draws Cautious Retail Mood After Barclays ‘Underweight’ Call: ‘Added To The Biotech Graveyard’
a month ago - By: Summit Therapeutics
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025
a month ago - By: Summit Therapeutics
Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China
a month ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
a month ago - By: Summit Therapeutics
Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer
a month ago - By: Summit Therapeutics
Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025
a month ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
2 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
2 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
2 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
2 months ago - By: Summit Therapeutics
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2 months ago - By: Summit Therapeutics
HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025
2 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
Please enable JavaScript to continue using this application.